Vitamin K and the Bioenergetic Stack: K1, K2 (MK-4), and Metabolic Function

Vitamin K occupies a peculiar position in popular nutritional discourse. Most people have heard of it in one of two contexts: as the fat-soluble vitamin that "helps blood clot," or as the K2 form that is supposed to direct calcium toward bone and away from arteries. Both of those framings capture something real, but they leave out a dimension that the bioenergetic-research community has identified as mechanistically important: the function of K2 - specifically the MK-4 sub-form - inside the mitochondrion.

The bioenergetic-research framework, which treats chronic illness through the lens of mitochondrial electron transport, oxidative phosphorylation, and cellular energy sufficiency, has placed K2 (MK-4) in a distinct position within the supplement stack. The argument is not primarily about calcium routing or coagulation. It is about electron transport chain support - the same category of function that the same research community attributes to methylene blue, ubiquinol, and niacinamide. Understanding why requires a careful look at the K vitamin family, the pharmacokinetic differences between the sub-forms, and the published mitochondrial literature from the 2010s that shifted how K2 is understood at the cellular level.

Research framing. This guide reviews vitamin K from a research-context standpoint. Compounds and protocols discussed are presented for informational and educational purposes. All products available on this site are for research purposes only and are not intended to diagnose, treat, cure, or prevent any disease. See our /faq#legality page for full terms.

What Is Vitamin K?

Vitamin K is a fat-soluble vitamin that functions as a cofactor for a specific class of enzymatic reactions: gamma-carboxylation of glutamate residues in proteins. This post-translational modification - adding a carboxyl group to specific glutamate residues - is required to activate a defined set of proteins collectively called vitamin K-dependent proteins. The most familiar of these are the coagulation factors (II, VII, IX, X, protein C, protein S, protein Z), which accounts for the blood-clotting association. But the vitamin K-dependent proteins also include osteocalcin (bone) and matrix Gla protein (MGP, vascular) - the proteins that matter most from a bioenergetic and cardiovascular standpoint.

Two main forms of vitamin K exist in nature, and the distinction between them is not superficial. It drives the entire logic of the bioenergetic community's K2 preference.

Vitamin K1 (phylloquinone) is the plant-derived form. Green leafy vegetables - kale, spinach, broccoli, Brussels sprouts - are the primary dietary sources, and K1 is the dominant form in the Western diet. Pharmacokinetically, K1 has a short half-life and is heavily taken up by the liver, where it preferentially activates the hepatic coagulation factors. Extra-hepatic tissue - bone, vasculature, brain - receives relatively little K1 under normal dietary conditions. The liver clears it efficiently before it reaches peripheral tissues in meaningful concentrations.

Vitamin K2 (menaquinone) is the animal- and bacterial-derived form. It exists in multiple sub-forms designated MK-4 through MK-13 (with MK-4 and MK-7 being the most studied), distinguished by the length and degree of saturation of their isoprenoid side chains. This structural variation is not incidental - it directly determines tissue distribution, half-life, and the cellular contexts in which each form operates. K2 sub-forms, particularly MK-4, are distributed to extra-hepatic tissues: bone, vasculature, kidney, brain, and reproductive organs. This extra-hepatic distribution is precisely what makes K2 the form of interest for cardiovascular and mitochondrial research contexts.

Dietary K2 sources include hard and soft cheeses, egg yolks, liver, and fermented foods. Natto - a Japanese fermented soybean preparation - is by far the highest dietary source of K2 as MK-7. Most Western diets are significantly lower in K2 than in K1, and the extra-hepatic K2-dependent proteins are correspondingly undercarboxylated in populations relying on dietary K2 alone.

MK-4 vs MK-7: The Bioenergetic Choice

Not all vitamin K2 is the same, and the MK-4 versus MK-7 distinction matters considerably in the bioenergetic-research context.

MK-4 (menaquinone-4) is the short-chain K2 form - the form that mammals, including humans, synthesize endogenously from K1. The body converts dietary K1 into MK-4 through a direct conversion pathway that does not require gut bacteria; it is a tissue-level synthesis occurring in the brain, testes, pancreas, and arterial walls among other locations. This endogenous synthesis distinguishes MK-4 from all longer-chain menaquinones: MK-4 is the form the human body makes and deposits into specific tissues. Its half-life in serum is short - approximately one to two hours - meaning serum levels rise and fall quickly after dosing, but tissue distribution occurs during the absorption window and tissue retention is substantially longer. MK-4's short serum half-life is not a weakness in the bioenergetic context; it reflects the rapid tissue uptake that drives the extra-hepatic distribution the protocol community values.

MK-7 (menaquinone-7) is a long-chain K2 form derived primarily from bacterial fermentation - it is the dominant K2 form in natto. Its half-life in serum is dramatically longer: approximately 70 to 72 hours. This long half-life means once-daily dosing produces stable serum pools. MK-7 has real cardiovascular research support, particularly for osteocalcin carboxylation, and is the form used in several of the most-cited K2 bone and cardiovascular trials because its stable serum levels make it pharmacologically convenient for research design. However, MK-7 is not endogenous - the human body does not synthesize MK-7, and it is not the form found naturally in human tissues. It pools in serum rather than distributing rapidly to peripheral tissues the way MK-4 does.

The bioenergetic-research community's preference for MK-4 reflects a physiological-specificity argument: MK-4 is the form the organism makes, the form present in mitochondria-dense tissues at baseline, and the form that the published mitochondrial electron transport literature has studied specifically. MK-7 does not appear in the same mitochondrial literature context. When the research community discusses K2 as a mitochondrial cofactor, it is discussing MK-4.

Supplemental MK-4 doses used in the research context are typically in the milligram range - substantially higher than the microgram doses used in MK-7 studies and nutritional-sufficiency K2 research. This dose-form difference is important context when evaluating the research literature.

Vitamin K2 and Mitochondrial Function

The mitochondrial dimension of K2 (MK-4) research is the least well-known outside the bioenergetic community, and it rests on a specific body of literature that began attracting attention in the early 2010s.

The core finding - published in peer-reviewed research and replicated in animal models - is that MK-4 can serve as an alternative electron carrier in the mitochondrial electron transport chain. Specifically, MK-4 can carry electrons between the NADH/FADH2 entry points (Complexes I and II) and Complex III. In the normal electron transport chain architecture, ubiquinol (CoQ10) performs this function: it accepts electrons from Complex I and Complex II and carries them to Complex III. MK-4 appears capable of serving a partially overlapping role as an electron shuttle within the inner mitochondrial membrane environment.

This finding emerged from research on mitochondrial electron transport dysfunction, particularly in the context of conditions in which Complex I activity is impaired. When Complex I function is compromised - a finding in post-viral fatigue, neurodegenerative conditions, and aging-related mitochondrial decline - the upstream portion of the electron transport chain backs up, NADH cannot be efficiently oxidized, and electron flow stalls. Alternative electron carriers that can bypass or circumvent this impairment are mechanistically important in these contexts.

MK-4's capacity to carry electrons in this region of the chain places it in a category alongside ubiquinol (CoQ10) as an inner-membrane electron carrier - though their mechanisms are not identical and they operate in overlapping but distinct domains. The bioenergetic-research community treats this as a rationale for stacking MK-4 alongside ubiquinol rather than treating them as alternatives. Both are fat-soluble, both are membrane-associated, and both participate in electron transport - but at different positions and through different chemical mechanisms.

The mitochondrial electron carrier evidence for MK-4 is animal- and cell-model data at this point. The specific RCT evidence base for mitochondrial electron transport restoration by MK-4 in human chronic illness is not yet developed in the way that the CoQ10 literature is. The bioenergetic-research community treats the animal and cell-model findings as mechanistically informative rather than as established clinical intervention. That distinction is maintained throughout this guide.

Beyond the electron transport role, MK-4's mitochondrial connection extends to its endogenous tissue distribution. The tissues that synthesize MK-4 endogenously - brain, testes, pancreas, arterial wall - are uniformly high in mitochondrial density or mitochondrial activity. This co-localization is circumstantially consistent with a mitochondrial function for MK-4, though correlation is not mechanism.

Vitamin K2 and Thyroid Hormone: The Bioenergetic Pairing

The pairing of K2 (MK-4) with thyroid hormone - particularly slow-release T3 - has a mechanistic logic that the bioenergetic-research community finds compelling, and it is worth articulating precisely.

Thyroid hormone, specifically T3 (triiodothyronine), is a primary regulator of mitochondrial biogenesis and electron transport chain expression. T3 acts on nuclear thyroid hormone receptors that directly regulate the transcription of mitochondrial proteins, including components of Complexes I through V. Adequate T3 signaling is required for the organism to express the electron transport chain machinery at full density. In states of hypothyroidism or T3 deficiency - including the low-T3 patterns seen in chronic illness even with normal TSH values - mitochondrial electron transport chain density is reduced, oxidative phosphorylation is downregulated, and cellular ATP output falls.

Slow-release T3 (SR-T3), the compound available at Wilson's SR-T3 Combo Kit, addresses the T3-signaling deficit directly. SR-T3 provides T3 in a formulation designed to maintain more stable plasma levels over time than immediate-release liothyronine (Cytomel), reducing the peak-trough cycling that immediate-release T3 creates. The sustained T3 availability is intended to provide more consistent nuclear receptor occupancy and therefore more consistent mitochondrial gene expression signaling. For a complete treatment of SR-T3, see the sustained-release T3 complete guide.

The K2 (MK-4) pairing enters through the following logic: T3 drives upregulation of the electron transport chain machinery - it increases demand on the mitochondrial electron transport system by increasing the number and activity of these complexes. K2 (MK-4), via its documented electron carrier function in the inner mitochondrial membrane, supports the electron transport infrastructure that T3 is upregulating. T3 drives the demand side; K2 (MK-4) supports the supply side. The pairing is mechanistically coherent in a way that purely antioxidant supplements are not, because MK-4's function is not to neutralize reactive oxygen species but to participate directly in the electron transport process.

Research subjects working with SR-T3 protocols commonly report including K2 (MK-4) as a cofactor in the mitochondrial-support layer of the stack. The rationale given in research forum discussion is exactly this demand-supply framing: thyroid hormone creates the conditions for electron transport chain activity, and MK-4 provides additional electron-shuttling capacity within the inner membrane to support that activity. This is not an RCT-validated combination in the chronic-illness context. It is a mechanistically motivated protocol that the bioenergetic-research community has developed from the available literature.

For those exploring SR-T3 as part of a bioenergetic protocol, Wilson's SR-T3 Combo Kit is the product available on this site.

Calcium Trafficking: K2 and Cardiovascular Research

The cardiovascular research context for K2 is more extensively developed than the mitochondrial literature and provides the strongest population-level evidence for the bioenergetic community's K2 emphasis.

The mechanism centers on two K2-dependent proteins: matrix Gla protein (MGP) and osteocalcin.

Matrix Gla protein is produced by vascular smooth muscle cells and chondrocytes. In its carboxylated (activated) form, MGP is a potent inhibitor of vascular and soft-tissue calcification - it binds calcium ions and calcium crystal nucleation sites within the arterial wall, preventing calcium from precipitating into the vessel wall. Undercarboxylated MGP (inactive MGP, the result of insufficient vitamin K2 activity) cannot perform this inhibitory function. Vascular calcification proceeds when MGP carboxylation is inadequate. The MGP-K2 relationship is dose-dependent: higher K2 intake produces higher carboxylated MGP fractions and lower undercarboxylated MGP, the latter being the biomarker for inadequate K2 status.

Osteocalcin is produced by osteoblasts (bone-forming cells). In its carboxylated form, osteocalcin binds calcium within the bone matrix and directs calcium deposition into bone mineral. Undercarboxylated osteocalcin is the marker of inadequate K2 activity at the bone level. The directional logic is straightforward: K2-dependent protein activation routes calcium to bone (via osteocalcin) while simultaneously suppressing calcium deposition in soft tissue (via MGP). K2 deficiency inverts this: calcium enters soft tissue while bone matrix formation is suboptimal.

The Rotterdam Study (Geleijnse et al., 2004) was a pivotal population observation. In a cohort of over 4,800 subjects followed for seven to ten years, high dietary K2 intake was associated with significantly reduced cardiovascular mortality and aortic calcification, while K1 intake showed no such association. This K1/K2 divergence is important: it supports the hypothesis that the extra-hepatic tissue effects of K2 are what matter for cardiovascular outcomes, not the hepatic coagulation-factor activation that K1 efficiently provides. Subsequent intervention trials with MK-7 supplementation confirmed that supplemental K2 reduces progression of arterial stiffness and reduces undercarboxylated MGP fractions in a dose-dependent way.

The bioenergetic-research community's emphasis on K2 is reinforced by this cardiovascular data. The calcium-routing function of K2 is not separate from the metabolic context - arterial calcification and vascular rigidity directly impair tissue perfusion and oxygen delivery, which compounds any mitochondrial insufficiency. Maintaining vascular compliance through adequate MGP carboxylation is metabolically coherent with the broader bioenergetic framework's emphasis on adequate tissue perfusion.

Dose Ranges in Research Context

The dose ranges in the table above reflect what appears in the bioenergetic-research forum literature, not clinical trials in conventional medicine. The conventional clinical-nutrition doses for K2 are lower, typically in the 90-360 mcg range for MK-7 and the 1-5 mg range for MK-4, reflecting a different target - achieving nutritional sufficiency rather than the pharmacological mitochondrial-cofactor use case the bioenergetic community is investigating.

Because K2 is fat-soluble, absorption is meaningfully improved when taken with a meal containing fat. The short half-life of MK-4 in serum means that taking it with the largest meal of the day or splitting across two meals (for higher-range protocols) maximizes tissue exposure during the absorption window. Unlike water-soluble vitamins, skipped doses on an empty-stomach basis represent a real loss of the dose rather than merely delayed absorption.

Tolerability and Side-Effect Profile

Vitamin K in both K1 and K2 forms has a well-established tolerability profile at nutritional and moderate supplemental doses. No established upper tolerable intake level (UL) has been set by major health authorities for K1 or K2 in the general population at nutritional dose ranges, reflecting the low observed adverse-event rate at those doses. At the higher MK-4 doses discussed in the research community - the 15-90 mg range - long-term safety data in human subjects is less comprehensive than at nutritional doses, and researchers working at these levels do so with that caveat in mind.

The one critical interaction is with warfarin (Coumadin), and it is not negotiable.

Warfarin is a vitamin K antagonist - its anticoagulant mechanism works precisely by blocking vitamin K-dependent gamma-carboxylation of coagulation factors. Any exogenous vitamin K supplementation, in any form (K1 or K2) and at any substantial dose, directly antagonizes warfarin's mechanism of action. The anticoagulant effect of warfarin will be reduced - potentially substantially reduced - by vitamin K supplementation, and this reduction in anticoagulation can result in thrombotic events in patients whose warfarin is being used to prevent clotting (atrial fibrillation, mechanical heart valves, deep vein thrombosis, pulmonary embolism, and similar indications).

Research subjects on warfarin (Coumadin) or any other vitamin K antagonist anticoagulant MUST NOT use vitamin K supplementation without direct medical supervision and INR monitoring. This is not a precautionary statement. It is a pharmacological reality: supplemental vitamin K will reduce warfarin effect in a dose-dependent way, and the consequences of under-anticoagulation in a warfarin patient can be life-threatening. There are no exceptions to this principle.

For research subjects not on anticoagulants, vitamin K supplementation has not been associated with procoagulant events - supplemental K2 at research-context doses does not cause thrombosis in people with normal coagulation. The concern is specifically and exclusively the warfarin interaction.

No meaningful drug interactions beyond anticoagulants have been identified for K2 (MK-4) in the published literature. Fat malabsorption syndromes (Crohn's disease, celiac disease, short bowel syndrome, cholestatic liver disease) reduce K2 absorption because fat-soluble vitamins require intact fat absorption pathways.

The Ray Peat Context

The bioenergetic-research framework associated with the later work of Ray Peat and the community that has extended it treats vitamin K2 (MK-4) as a foundational molecule within the broader mitochondrial-cofactor and calcium-trafficking layers of the protocol stack.

Peat-aligned discussion treats the electron transport chain as the primary site of metabolic interest, and the bioenergetic protocol addresses this from multiple angles simultaneously. Thyroid hormone (typically T3 in slow-release form) provides the upstream transcriptional signal that calibrates electron transport chain density and metabolic rate. Mitochondrial cofactors - ubiquinol, niacinamide, and MK-4 - provide the molecular infrastructure the electron transport chain requires to operate efficiently once it has been upregulated. Calcium regulation - through MK-4's activation of MGP and osteocalcin - is not treated as a separate concern but as part of the same metabolic coherence: the same cells that depend on electron transport chain function also depend on proper calcium signaling, and vascular calcification that impairs perfusion compounds mitochondrial insufficiency.

The bioenergetic-protocol community commonly discusses K2 (MK-4) in combination with the full bioenergetic stack: thyroid hormone (T3, T2, or SR-T3), pregnenolone, cyproheptadine, and methylene blue. The rationale for each is mechanistically distinct - MK-4 is in the stack because of the electron transport carrier function and the calcium-routing function, not because it is a general antioxidant or an adaptogen.

The complete framework context for this K2 discussion, including how the molecules in the bioenergetic protocol relate to each other and the research basis for the protocol as a whole, is covered in the Ray Peat protocol complete 2026 research guide.

What Research Has and Hasn't Established

Established:

K1 and K2 have different bioavailability, half-lives, and tissue distribution profiles - this is documented in pharmacokinetic research and is the scientific basis for distinguishing between the forms. K2 (MK-4) preferentially distributes to extra-hepatic tissues including vasculature, bone, and brain, while K1 is preferentially taken up by the liver. Vitamin K is an essential cofactor for gamma-carboxylation, and this post-translational modification is required for the activation of all vitamin K-dependent proteins. K2 (MK-4) activates osteocalcin and matrix Gla protein through gamma-carboxylation - this is established biochemistry with direct tissue-level functional consequences documented in intervention trials. The cardiovascular association of dietary K2 intake is supported by the Rotterdam Study and subsequent research, including controlled trials with MK-7 supplementation.

Hypothesis:

K2 (MK-4) as a mitochondrial electron carrier functioning between Complex I/II and Complex III - the mechanism that is the primary rationale for its bioenergetic-protocol use - is supported by cell and animal model research from the early 2010s. The mechanistic argument is coherent, the published findings in non-human models are genuine, and the bioenergetic-research community has built its K2 protocol on this foundation. However, RCT-validated evidence for K2 (MK-4) as a mitochondrial electron transport intervention in human chronic illness - specifically paired with thyroid hormone in a chronic-fatigue or post-viral recovery context - does not yet exist. The pairing with SR-T3 as a demand-supply mitochondrial cofactor stack is mechanistically motivated but not clinically validated in controlled trials for this use case.

Not endorsed by mainstream endocrinology:

The bioenergetic-protocol use of K2 (MK-4) in the milligram dose range as a mitochondrial electron transport cofactor, particularly as part of a stack including thyroid hormone, is outside the scope of mainstream clinical endocrinology. Mainstream endocrinology recognizes K2's role in bone and cardiovascular health through gamma-carboxylation. The extension of the K2 mechanism into an electron transport chain cofactor role at pharmacological doses, paired with thyroid hormone for the treatment or investigation of chronic fatigue or metabolic insufficiency, is a research-community development that proceeds outside established clinical guidelines.

Frequently Asked Questions

What is the difference between vitamin K1 and K2?

Vitamin K1 (phylloquinone) is the plant-derived form found in green leafy vegetables. It is rapidly taken up by the liver, where it preferentially activates the coagulation factors. Vitamin K2 (menaquinone) is the animal- and bacterial-derived form that distributes to extra-hepatic tissues including bone, vasculature, and brain. K2 activates extra-hepatic vitamin K-dependent proteins including osteocalcin and matrix Gla protein, which K1 does not reach in meaningful concentrations. The two forms are not interchangeable for extra-hepatic functions.

What is the difference between MK-4 and MK-7?

MK-4 and MK-7 are both forms of vitamin K2 (menaquinone) distinguished by the length of their isoprenoid side chains. MK-4 is the short-chain form that mammals synthesize endogenously from K1. It has a short serum half-life (one to two hours) and distributes rapidly to peripheral tissues. MK-7 is a long-chain form derived from bacterial fermentation (primarily natto). It has a serum half-life of approximately 70 hours, producing stable serum pools with once-daily dosing. MK-4 is the form found in animal tissues; MK-7 is not endogenously synthesized by humans. The bioenergetic-research literature on mitochondrial electron transport specifically concerns MK-4, not MK-7.

Why does the bioenergetic framework prefer MK-4?

Three reasons. First, MK-4 is the endogenous animal-kingdom form of K2 - the form the human body synthesizes and deposits into metabolically active tissues. Second, the published mitochondrial electron carrier research that forms the basis of the bioenergetic protocol's K2 rationale was conducted with MK-4 specifically. Third, MK-4's rapid tissue distribution (as opposed to MK-7's serum pooling) is consistent with the extra-hepatic tissue targets - bone, vasculature, brain - that the bioenergetic protocol is concerned with.

How much vitamin K2 do bioenergetic researchers use?

The research forum discussion of MK-4 dosing spans a range from 5 to 90 mg per day, with 15-45 mg being the most commonly reported standard protocol range. These are milligram doses - substantially higher than the microgram doses used in nutritional-sufficiency trials with MK-7. MK-4 requires dietary fat for absorption. The dose ranges discussed in the research community are not established clinical recommendations.

Can vitamin K2 be combined with thyroid hormone?

In terms of pharmacological interaction, vitamin K2 (MK-4) does not directly affect thyroid hormone metabolism or thyroid hormone receptor signaling, and thyroid hormone does not affect vitamin K metabolism. There is no known adverse interaction. The bioenergetic-research community combines K2 (MK-4) with thyroid hormone (particularly SR-T3) on the basis of a mechanistic demand-supply argument: T3 drives mitochondrial electron transport chain upregulation while MK-4 supports electron carrier capacity within that chain. This combination is not clinically validated in controlled trials.

Does vitamin K2 cause blood clots?

No. In research subjects without anticoagulant therapy, vitamin K supplementation does not produce a procoagulant state or increase the risk of thrombosis. The coagulation factors are tightly regulated and are not overactivated by vitamin K supplementation in a healthy system. The blood-clotting concern around vitamin K is specifically its interaction with warfarin - K2 supplementation antagonizes warfarin's anticoagulant effect, which can lead to underanticoagulation in patients who depend on warfarin. This is not the same as K2 causing clots in the general population.

Should I avoid vitamin K2 if I take warfarin?

Yes. Vitamin K supplementation in any form at any substantial dose antagonizes warfarin's mechanism of action. Warfarin works by blocking vitamin K-dependent gamma-carboxylation of coagulation factors. Supplemental K2 provides the vitamin K that warfarin is designed to block, directly undermining the anticoagulant effect. This interaction can result in INR values falling below the therapeutic range and in thrombotic events. Research subjects on warfarin (Coumadin) or any other vitamin K antagonist must not use vitamin K2 supplementation without direct medical supervision and regular INR monitoring.

Is vitamin K2 safer than vitamin K1?

At nutritional to moderate supplemental doses, both forms have similar low adverse-event profiles. Neither form has an established upper tolerable intake level (UL) from major health authorities at nutritional doses. K2 at the higher milligram doses discussed in the bioenergetic-research context represents a less well-characterized safety territory than K1 at nutritional doses, because fewer long-term human studies have evaluated K2 at those levels. The warfarin interaction applies to both K1 and K2 - both antagonize warfarin. At research protocol doses, K2 (MK-4) is considered by the research community to be well-tolerated based on available data, but this should not be interpreted as a clinical endorsement of high-dose K2 as safe for all populations.

Closing Note

Vitamin K2 (MK-4) is one of the few fat-soluble molecules with documented participation in mitochondrial electron transport alongside its well-established roles in calcium trafficking through gamma-carboxylation of osteocalcin and matrix Gla protein. The bioenergetic-research community has placed it in the protocol stack on the basis of that electron transport role, paired with thyroid hormone as part of a mechanistically coherent demand-supply framework for mitochondrial support.

For the complete bioenergetic protocol context, including the role of thyroid hormone, pregnenolone, cyproheptadine, and methylene blue alongside K2 (MK-4), see the Ray Peat protocol complete 2026 research guide. For the slow-release T3 that the protocol community pairs with K2 (MK-4) as the thyroid component of the stack, see Wilson's SR-T3 Combo Kit. To browse all available research compounds, visit the product catalog.